DAVITA INC.DVA
時価総額
$90.7億
PER
透析・腎ケアサービスの米国大手。外来透析センターと統合腎ケアプログラムを展開。2024年11月にAPACジョイントベンチャー取得で買収。2024年12月31日時点で約80,300人の患者を受け入れ、米州・欧州・アジアで展開。
| 2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net income | 484 | 573 | 641 | 757 | 863 | 427 | 1,033 | 831 | 333 | 1,021 | 995 | 1,212 | 782 | 957 | 1,251 |
| Depreciation and amortization | - | - | - | - | - | - | - | - | 591 | 615 | 630 | 681 | 733 | 745 | 724 |
| Impairment charges | - | - | - | - | - | 210 | 296 | 982 | 62 | 125 | - | - | - | 26 | - |
| Debt Refinancing Charges | - | - | - | - | - | - | - | - | - | - | 87 | - | - | 7 | 13 |
| Stock-based compensation expense | 46 | 49 | 45 | 60 | 57 | 57 | 38 | 35 | 73 | 68 | 91 | 102 | 95 | 112 | 103 |
| Deferred income taxes | 75 | 53 | 44 | -25 | 211 | 62 | 52 | -395 | 274 | 42 | 241 | 60 | -76 | -39 | -58 |
| Equity investment loss, net | 3 | -0 | -3 | -3 | -10 | -9 | -18 | -29 | -26 | -9 | -14 | -5 | -9 | -65 | -116 |
| Gain on changes in ownership interests | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 109 |
| Other non-cash losses and (gains), net | - | - | - | - | - | -45 | 7 | -67 | -82 | -50 | -1 | -11 | -22 | 9 | -13 |
| Accounts receivable | -55 | 89 | 48 | 60 | 41 | 203 | 152 | 156 | 81 | 80 | 21 | 138 | 148 | -172 | 30 |
| Inventories | 4 | -10 | -4 | 9 | 46 | 48 | -23 | 19 | -74 | -10 | 12 | -6 | 1 | 32 | -18 |
| Other current assets | 45 | -54 | -52 | 108 | 62 | -33 | 54 | 117 | -237 | -3 | 79 | -129 | -28 | 43 | -37 |
| Other long-term assets | - | - | - | -18 | -3 | -4 | -36 | 12 | -3 | -7 | 6 | 26 | 51 | 6 | 67 |
| Accounts payable | 4 | 84 | 41 | 17 | -3 | 31 | 12 | 27 | -36 | -85 | 37 | -30 | 87 | 27 | 2 |
| Accrued compensation and benefits | 40 | 77 | 18 | 38 | 97 | 55 | 68 | -78 | 84 | -15 | -21 | -17 | 35 | 56 | 15 |
| Other current liabilities | - | -52 | 11 | 79 | 84 | 113 | 176 | 2 | -157 | 182 | 106 | -94 | 90 | 27 | 47 |
| Income taxes | -46 | 77 | -130 | 33 | -60 | 24 | 62 | -52 | -24 | 96 | -87 | 37 | -24 | 2 | -44 |
| Other long-term liabilities | - | - | - | 66 | -2 | 33 | 31 | 11 | -1 | -31 | -20 | -7 | -16 | -8 | -7 |
| Net Cash Provided by (Used in) Operating Activities, Total | 840 | 1,180 | 1,101 | 1,773 | 1,459 | - | - | 1,907 | 1,772 | 2,072 | 1,979 | 1,931 | 1,565 | 2,059 | 2,022 |
| Additions of property and equipment | 274 | 400 | 550 | 618 | 641 | 708 | 829 | 905 | 987 | 767 | 675 | 641 | 603 | 568 | 555 |
| Acquisitions | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 246 |
| Proceeds from asset and business sales | - | - | - | - | - | 20 | 65 | 92 | 150 | 3,877 | 50 | 61 | 118 | 31 | 26 |
| Purchase of debt investments held-to-maturity | 57 | 38 | 7 | 1 | 473 | 1,710 | 1,133 | 231 | 6 | 101 | 151 | 31 | 130 | 37 | 15 |
| Purchase of other debt and equity investments | - | - | - | - | - | - | - | - | - | - | - | 3 | 4 | 10 | 9 |
| Proceeds from debt investments held-to-maturity | - | - | - | - | 141 | 1,637 | 1,241 | 492 | 35 | 95 | 151 | 16 | 71 | 100 | 23 |
| Proceeds from Sale and Maturity of Other Investments | - | - | - | - | - | - | - | - | - | - | - | 12 | 4 | 10 | 5 |
| Purchase of equity method investments | - | - | - | - | 35 | 18 | 27 | 5 | 19 | 9 | 22 | 14 | 32 | 276 | 5 |
| Distributions from equity method investments | - | - | - | - | 1 | 0 | - | 0 | 4 | 3 | 3 | 3 | 4 | 5 | 7 |
| Payments to Acquire Other Investments | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | - | - |
| Net Cash Provided by (Used in) Investing Activities, Total | -437 | -1,399 | -4,832 | -877 | -1,278 | - | - | -1,367 | -1,006 | 2,995 | -825 | -785 | -630 | -772 | -771 |
| Borrowings | 24,809 | 36,395 | 43,248 | 66,286 | 60,039 | 54,542 | 51,991 | 50,992 | 59,935 | 38,526 | 4,047 | 1,615 | 2,393 | 2,468 | 6,624 |
| Payments on long-term debt | - | - | - | 66,724 | 60,046 | 53,922 | 52,116 | 50,837 | 59,240 | 40,606 | 4,110 | 861 | 2,404 | 3,021 | 5,515 |
| Deferred and debt related financing costs | - | - | - | - | - | - | - | - | - | - | 106 | 9 | 0 | 70 | 51 |
| Purchase of treasury stock | 618 | 323 | - | - | - | 550 | 1,098 | 803 | 1,162 | 2,384 | 1,458 | 1,539 | 802 | 272 | 1,386 |
| Distributions to noncontrolling interests | - | - | - | - | - | 175 | 192 | 211 | 196 | 233 | 253 | 244 | 268 | 281 | 337 |
| Net Proceeds From Issuance Of Stock To Employees | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20 |
| Payment, Tax Withholding, Share-Based Payment Arrangement | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 134 |
| Contributions from noncontrolling interests | - | - | - | - | - | 55 | 48 | 75 | 52 | 57 | 43 | 32 | 15 | 15 | 14 |
| Proceeds from Noncontrolling Interests | 3 | 10 | 2 | 8 | 4 | - | - | 3 | 0 | - | - | 3 | 4 | 51 | 1 |
| Purchases of noncontrolling interests | 14 | 14 | 27 | 4 | 18 | 66 | 22 | 5 | 28 | 68 | 8 | 20 | 21 | 13 | 54 |
| Net cash used in financing activities | -82 | -247 | 3,872 | -483 | -165 | - | - | -766 | -625 | -4,696 | -1,847 | -1,083 | -1,121 | -1,170 | -817 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | - | - | - | - | - | - | - | - | -3 | -2 | -14 | -10 | -29 | 9 | -18 |
| Less: Net increase (decrease) in cash, cash equivalents and restricted cash | - | - | - | - | - | - | - | - | 137 | 369 | -707 | 53 | -216 | 126 | 415 |